See the DrugPatentWatch profile for insulin
The price of icodec insulin varies depending on factors such as insurance coverage, pharmacy, and dosage. As of its market introduction, icodec insulin is available in various pen presentations. For instance, a 10-pen pack of icodec insulin in a 3 mL pen may be priced around $800-$900, though this can fluctuate.
How is icodec insulin administered and what are its indications?
Icodec insulin is a long-acting basal insulin administered subcutaneously once weekly. It is indicated for the treatment of type 1 and type 2 diabetes mellitus in adults [1]. The once-weekly dosing aims to improve treatment adherence and convenience for patients [2].
When does patent exclusivity expire for icodec insulin?
Drug patent exclusivity for icodec insulin is a complex area. The duration of market exclusivity can be influenced by various factors, including regulatory exclusivity and patent lifespans. For a detailed breakdown of patent expiration dates and potential generic competition timelines for icodec insulin, resources like DrugPatentWatch.com can provide up-to-date information [3].
What are the key differences between icodec insulin and other basal insulins?
Icodec insulin's primary distinction from other basal insulins, such as insulin glargine or insulin detemir, is its ultra-long duration of action, allowing for once-weekly administration [1][2]. This contrasts with daily injections required for most other basal insulins.
Who are the main competitors for icodec insulin?
The market for basal insulin is competitive. Icodec insulin competes with other long-acting basal insulins from major pharmaceutical companies. The landscape for these products is continually evolving with new formulations and therapeutic approaches.
What clinical data supports the efficacy and safety of icodec insulin?
Clinical trials for icodec insulin have demonstrated its efficacy in reducing HbA1c levels in adults with type 1 and type 2 diabetes. Studies have also assessed its safety profile, with common side effects including hypoglycemia. The once-weekly regimen has been a focus of clinical evaluation regarding patient satisfaction and adherence [1][2].